Multicenter Investigation of Xanthine Oxidase Inhibitor Efficacy for CKD patients with Hyperuricemia

Trial Profile

Multicenter Investigation of Xanthine Oxidase Inhibitor Efficacy for CKD patients with Hyperuricemia

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2017

At a glance

  • Drugs Febuxostat (Primary) ; Topiroxostat (Primary)
  • Indications Hyperuricaemia
  • Focus Therapeutic Use
  • Acronyms MIE-CKD
  • Most Recent Events

    • 21 Jan 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 13 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top